WallStSmart

Amgen Inc (AMGN)vsGE Vernova LLC (GEV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE Vernova LLC generates 4% more annual revenue ($38.07B vs $36.75B). AMGN leads profitability with a 21.0% profit margin vs 12.8%. AMGN appears more attractively valued with a PEG of 2.33. AMGN earns a higher WallStSmart Score of 70/100 (B-).

AMGN

Strong Buy

70

out of 100

Grade: B-

Growth: 8.0Profit: 8.5Value: 10.0Quality: 5.0
Piotroski: 4/9

GEV

Buy

55

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 2.7Quality: 4.3
Piotroski: 4/9Altman Z: 1.02
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMGNUndervalued (+46.8%)

Margin of Safety

+46.8%

Fair Value

$665.50

Current Price

$353.93

$311.57 discount

UndervaluedFair: $665.50Overvalued
GEVOvervalued (-6.0%)

Margin of Safety

-6.0%

Fair Value

$829.76

Current Price

$923.69

$93.93 premium

UndervaluedFair: $829.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMGN5 strengths · Avg: 9.6/10
Return on EquityProfitability
106.1%10/10

Every $100 of equity generates 106 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

EPS GrowthGrowth
112.1%10/10

Earnings expanding 112.1% YoY

Market CapQuality
$187.83B9/10

Large-cap with strong market position

Profit MarginProfitability
21.0%9/10

Keeps 21 of every $100 in revenue as profit

GEV3 strengths · Avg: 9.3/10
Market CapQuality
$246.74B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
42.6%10/10

Every $100 of equity generates 43 in profit

Free Cash FlowQuality
$1.81B8/10

Generating 1.8B in free cash flow

Areas to Watch

AMGN2 concerns · Avg: 3.0/10
PEG RatioValuation
2.334/10

Expensive relative to growth rate

Price/BookValuation
22.0x2/10

Trading at 22.0x book value

GEV4 concerns · Avg: 2.5/10
Revenue GrowthGrowth
3.8%4/10

3.8% revenue growth

PEG RatioValuation
3.342/10

Expensive relative to growth rate

P/E RatioValuation
51.3x2/10

Premium valuation, high expectations priced in

Price/BookValuation
22.3x2/10

Trading at 22.3x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : AMGN

The strongest argument for AMGN centers on Return on Equity, Operating Margin, EPS Growth. Profitability is solid with margins at 21.0% and operating margin at 30.5%.

Bull Case : GEV

The strongest argument for GEV centers on Market Cap, Return on Equity, Free Cash Flow.

Bear Case : AMGN

The primary concerns for AMGN are PEG Ratio, Price/Book.

Bear Case : GEV

The primary concerns for GEV are Revenue Growth, PEG Ratio, P/E Ratio. A P/E of 51.3x leaves little room for execution misses.

Key Dynamics to Monitor

AMGN profiles as a mature stock while GEV is a value play — different risk/reward profiles.

AMGN is growing revenue faster at 8.6% — sustainability is the question.

GEV generates stronger free cash flow (1.8B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AMGN scores higher overall (70/100 vs 55/100), backed by strong 21.0% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amgen Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.

Visit Website →

GE Vernova LLC

INDUSTRIALS · SPECIALTY INDUSTRIAL MACHINERY · USA

GE Vernova LLC, an energy business company, generates electricity.

Visit Website →

Want to dig deeper into these stocks?